Low salivary testosterone levels in patients with breast cancer
By: Constantine Dimitrakakis, David Zava, Spyros Marinopoulos, Alexandra Tsigginou, Aris Antsaklis and Rebecca Glaser

BMC Cancer 2010, 10:547 doi:10.1186/1471-2407-10-547
Published: 11 October 2010

Abstract (Provisional)

Background

Correlation between circulating sex steroid levels and breast cancer has been controversial, with measurement of free, or bioavailable hormone rarely available. Salivary hormone levels represent the bioavailable fraction. To further elucidate the role of endogenous hormones in breast cancer, we aimed to assess correlation between salivary sex steroid levels and breast cancer prevalence.

Methods

Salivary hormone levels of testosterone (T), Estradiol (E2), Progesterone (P), Estriol (E3), Estrone (E1), DHEAS and Cortisol (C) were measured by Enzyme Immunoassay (EIA) in 357 women with histologically verified breast cancer and 184 age-matched control women.

Results

Salivary T and DHEAS levels were significantly lower in breast cancer cases vs. controls (27.2+13.9 vs. 32.2+17.5 pg/ml, p<0.001 for T and 5.3+4.3 vs. 6.4+4.5 ng/ml, p=0.007 for DHEAS). E2 and E1 levels were elevated and E3 levels were lowered in cases vs. controls.

Conclusions

Salivary T levels, representing the bioavailable hormone, are significantly lower in women with breast cancer compared to age-matched control women. These findings support the protective role of biovailable testosterone in counteracting the proliferative effects of estrogens on mammary tissue.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements